Search
Bordetella pertussis pertactin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10992ApprovedInvestigationalMixtures: Repevax Injektionssuspension in einer FertigspritzeInterferon Kappa
go.drugbank.com/drugs/DB15749Experimentala 27-amino acid signal peptide conserved in type I interferons. … This gene encoding for this interferon is expressed in human epidermal keratinocytes.
Candoxatrilat
go.drugbank.com/drugs/DB11623ExperimentalA potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure.
Rabies virus inactivated antigen, A
go.drugbank.com/drugs/DB10283ApprovedInvestigationalIt is an active immunization against rabies that can be administered pre- or post-exposure to the rabies virus. … Rabies virus inactivated antigen, A is an inactivated virus vacine for the intramuscular injection.
Cethromycin
go.drugbank.com/drugs/DB06419InvestigationalCethromycin is a 3-keto (ketolide) derivative of erythromycin A with an 11,12-carbamate group and an O-6-linked aromatic ring system. … [L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA.
MP4
go.drugbank.com/drugs/DB05313InvestigationalMP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. … It is free of harmful vasoactivity and provides targeted oxygen delivery to tissues at risk of oxygen deprivation.
Pardoprunox
go.drugbank.com/drugs/DB12061InvestigationalPardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced Stage Parkinson's Disease.
Barnidipine
go.drugbank.com/drugs/DB09227InvestigationalIt is available in modified-release oral tablets under the brand name Vasexten to be taken once daily in the morning. … Barnidipine has a gradual onset of action and is shown to be well tolerated in patients. It does not produce reflex tachycardia [A7842].
Rolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalBy blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.